Pharmacogenetics of FSH Action in the Female

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2019 Jul 12

PMID 31293516

Citations 16

Authors

Alessandro Conforti

Alberto Vaiarelli

Danilo Cimadomo

Francesca Bagnulo

Stefania Peluso

Luigi Carbone

Francesca Di Rella

Giuseppe De Placido

Filippo Maria Ubaldi

Ilpo Huhtaniemi

Carlo Alviggi

Affiliations

Soon will be listed here.

Abstract

The purpose of a pharmacogenomic approach is to tailor treatment on the basis of an individual human genotype. This strategy is becoming increasingly common in medicine, and important results have been obtained in oncologic and antimicrobial therapies. The rapid technological developments and availability of innovative methodologies have revealed the existence of numerous genotypes that can influence the action of medications and give rise to the idea that a true "individualized" approach could become in the future a reality in clinical practice. Moreover, compared to the past, genotype analyses are now more easily available at accessible cost. Concerning human reproduction, there is ample evidence that several variants of gonadotropins and their receptors influence female reproductive health and ovarian response to exogenous gonadotropins. In more detail, variants in genes of β (FSH-B) and its (FSH-R) seem to be the most promising candidates for a pharmacogenomic approach to controlled ovarian stimulation in assisted reproductive technologies. In the present review, we summarize the evidence regarding FSH-B and FSH-R variants, with special reference to their impact on reproductive health and assisted reproductive technology treatments.

Citing Articles

Pharmacogenomic of LH and its receptor: are we ready for clinical practice?.

Conforti A, Di Girolamo R, Guida M, Alviggi C, Casarini L Reprod Biol Endocrinol. 2025; 23(Suppl 1):29.

PMID: 40001128 PMC: 11863420. DOI: 10.1186/s12958-025-01359-2.

Bariatric Surgery as a Molecular Modulator: The Role of FSHR Polymorphisms in Enhancing eNOS Expression and Reproductive Hormone Dynamics in Women with Severe Obesity.

Voros C, Mavrogianni D, Bananis K, Karakasis A, Papahliou A, Topalis V Biomedicines. 2025; 13(1).

PMID: 39857651 PMC: 11763328. DOI: 10.3390/biomedicines13010067.

The most appropriate indicators of successful ovarian stimulation.

Roque M, Sunkara S Reprod Biol Endocrinol. 2025; 23(Suppl 1):5.

PMID: 39789602 PMC: 11714799. DOI: 10.1186/s12958-024-01331-6.

Patients with low prognosis in ART: a Delphi consensus to identify potential clinical implications and measure the impact of POSEIDON criteria.

Alviggi C, Humaidan P, Fischer R, Conforti A, Dahan M, La Marca A Reprod Biol Endocrinol. 2024; 22(1):122.

PMID: 39385174 PMC: 11465546. DOI: 10.1186/s12958-024-01291-x.

Application of Biomarkers in Obese Infertile Women: A Genetic Tool for a Personalized Treatment.

Voros C, Bananis K, Papapanagiotou A, Pouliakis A, Mavriki K, Gkaniatsos I J Clin Med. 2024; 13(8).

PMID: 38673534 PMC: 11051271. DOI: 10.3390/jcm13082261.

References

Perez Mayorga M, Gromoll J, Behre H, Gassner C, Nieschlag E, Simoni M . Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab. 2000; 85(9):3365-9. DOI: 10.1210/jcem.85.9.6789. View

Tong Y, Liao W, Roy A, Ng S . Association of AccI polymorphism in the follicle-stimulating hormone beta gene with polycystic ovary syndrome. Fertil Steril. 2000; 74(6):1233-6. DOI: 10.1016/s0015-0282(00)01616-2. View

Layman L, Porto A, Xie J, da Motta L, da Motta L, Weiser W . FSH beta gene mutations in a female with partial breast development and a male sibling with normal puberty and azoospermia. J Clin Endocrinol Metab. 2002; 87(8):3702-7. DOI: 10.1210/jcem.87.8.8724. View

Hoogendoorn B, Coleman S, Guy C, Smith K, Bowen T, Buckland P . Functional analysis of human promoter polymorphisms. Hum Mol Genet. 2003; 12(18):2249-54. DOI: 10.1093/hmg/ddg246. View

Yong E, Baird D, Hillier S . Mediation of gonadotrophin-stimulated growth and differentiation of human granulosa cells by adenosine-3',5'-monophosphate: one molecule, two messages. Clin Endocrinol (Oxf). 1992; 37(1):51-8. DOI: 10.1111/j.1365-2265.1992.tb02283.x. View

Behre H, Greb R, Mempel A, Sonntag B, Kiesel L, Kaltwasser P . Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics. 2005; 15(7):451-6. DOI: 10.1097/01.fpc.0000167330.92786.5e. View

Huhtaniemi I, Themmen A . Mutations in human gonadotropin and gonadotropin-receptor genes. Endocrine. 2005; 26(3):207-17. DOI: 10.1385/ENDO:26:3:207. View

Alviggi C, Mollo A, Clarizia R, De Placido G . Exploiting LH in ovarian stimulation. Reprod Biomed Online. 2006; 12(2):221-33. DOI: 10.1016/s1472-6483(10)60865-6. View

Alviggi C, Clarizia R, Mollo A, Ranieri A, De Placido G . Outlook: who needs LH in ovarian stimulation?. Reprod Biomed Online. 2006; 12(5):599-607. DOI: 10.1016/s1472-6483(10)61186-8. View

10.

Nakayama T, Kuroi N, Sano M, Tabara Y, Katsuya T, Ogihara T . Mutation of the follicle-stimulating hormone receptor gene 5'-untranslated region associated with female hypertension. Hypertension. 2006; 48(3):512-8. DOI: 10.1161/01.HYP.0000233877.84343.d7. View

11.

Orio Jr F, Ferrarini E, Cascella T, Dimida A, Palomba S, Gianetti E . Genetic analysis of the follicle stimulating hormone receptor gene in women with polycystic ovary syndrome. J Endocrinol Invest. 2007; 29(11):975-82. DOI: 10.1007/BF03349210. View

12.

Palermo R . Differential actions of FSH and LH during folliculogenesis. Reprod Biomed Online. 2007; 15(3):326-37. DOI: 10.1016/s1472-6483(10)60347-1. View

13.

Achrekar S, Modi D, Desai S, Mangoli V, Mangoli R, Mahale S . Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. Fertil Steril. 2008; 91(2):432-9. DOI: 10.1016/j.fertnstert.2007.11.093. View

14.

Grigorova M, Punab M, Ausmees K, Laan M . FSHB promoter polymorphism within evolutionary conserved element is associated with serum FSH level in men. Hum Reprod. 2008; 23(9):2160-6. PMC: 2517155. DOI: 10.1093/humrep/den216. View

15.

Simoni M, Tempfer C, Destenaves B, Fauser B . Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response. Hum Reprod Update. 2008; 14(5):459-84. PMC: 2515090. DOI: 10.1093/humupd/dmn024. View

16.

Achrekar S, Modi D, Desai S, Mangoli V, Mangoli R, Mahale S . Poor ovarian response to gonadotrophin stimulation is associated with FSH receptor polymorphism. Reprod Biomed Online. 2009; 18(4):509-15. DOI: 10.1016/s1472-6483(10)60127-7. View

17.

Overbeek A, Kuijper E, Hendriks M, Blankenstein M, Ketel I, Twisk J . Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. Hum Reprod. 2009; 24(8):2007-13. DOI: 10.1093/humrep/dep114. View

18.

Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A . Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010; 363(17):1621-30. DOI: 10.1056/NEJMoa1001283. View

19.

Lalioti M . Impact of follicle stimulating hormone receptor variants in fertility. Curr Opin Obstet Gynecol. 2011; 23(3):158-67. DOI: 10.1097/GCO.0b013e3283455288. View

20.

Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I . Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online. 2011; 22 Suppl 1:S67-72. DOI: 10.1016/S1472-6483(11)60011-4. View